Welcome to CDC stacks | Treatment and Mortality in Men with Localized Prostate Cancer: A Population-Based Study in California - 41907 | CDC Public Access
Stacks Logo
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
Help
Clear All Simple Search
Advanced Search
Treatment and Mortality in Men with Localized Prostate Cancer: A Population-Based Study in California
  • Published Date:
    2013
  • Source:
    Open Prost Cancer J. 6:1-9.
Filetype[PDF-1.60 MB]


Details:
  • Pubmed ID:
    23997838
  • Pubmed Central ID:
    PMC3758138
  • Description:
    Purpose

    To provide patients and physicians with population-based estimates of mortality from prostate cancer or other causes depending upon the primary treatment modality, stratified by patient age, tumor stage and grade.

    Methods

    We conducted a 10-year competing-risk analysis of 45,440 men diagnosed with clinically localized (T1 or T2) prostate cancer in California during 1995–1998. Information on patient characteristics, primary treatment and cause of death was obtained from the California Cancer Registry.

    Results

    In this population-based cohort, the most common primary treatment was surgery (40.4%), followed by radiotherapy (29.1%), conservative management (20.8%), and androgen deprivation therapy (ADT) monotherapy (9.8%). Prostate cancer mortality differed significantly (p < 0.0001) across treatment groups among patients <80 years at diagnosis with moderately or poorly differentiated disease; the 10-year disease-specific mortality rates were generally highest for men treated with ADT monotherapy [range: 3.3% (95% CI=0.8–12.5%) to 53.8% (95% CI=34.4–72.2%)], intermediate for men treated with conservative management [range: 1.7% (95% CI=0.7–4.6%) to 30.0% (95% CI=16.2–48.8%] or radiotherapy [range: 3.2% (95% CI=1.8–5.5%) to 18.3% (95% CI=15.1–22.0%)], and lowest for men treated with surgery [range: 1.2% (95% CI=0.8–1.7%) to 11.0% (95% CI=8.4–14.2%)].

    Conclusion

    The cause-specific mortality estimates provided by this observational study can help patients and physicians better understand the expected long-term outcomes of localized prostate cancer given the initial treatment choice and practice patterns in the general population.

  • Document Type:
  • Collection(s):
  • Funding:
    HHSN261201000035C/CA/NCI NIH HHS/United States
    U58 DP000807/DP/NCCDPHP CDC HHS/United States
    HHSN261201000035I/CA/NCI NIH HHS/United States
    K07 CA143047/CA/NCI NIH HHS/United States
    HHSN261201000034C/CA/NCI NIH HHS/United States
    HHSN261201000040C/CA/NCI NIH HHS/United States
    HHSN261201000040I/CA/NCI NIH HHS/United States
No Related Documents.
You May Also Like: